FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234095840> ?p ?o ?g. }

• W4234095840 endingPage "S59" @default.
• W4234095840 startingPage "S59" @default.
• W4234095840 abstract "Abstract Introduction Chronic granulomatous disease (CGD) is a rare immunodeficiency caused by mutations in the NADPH oxidase complex. Dysregulated immune function may cause inflammatory bowel disease (IBD). Patients with CGD-associated IBD may not respond to or may develop serious infections as a result of traditional IBD therapies such as vedolizumab and infliximab. Ustekinumab is approved for use in Crohn’s disease and ulcerative colitis however there is scarce data on its efficacy and safety in CGD. Aims To evaluate the efficacy and safety of ustekinumab for CGD-associated IBD. Methods A retrospective chart review was conducted on CGD patients followed at a single center who had consented to participate in a natural history study. Clinical, laboratory, and endoscopic data were extracted in those that had received ustekinumab for IBD. Results Eight patients were found. Four were male and four were female. Five were white, one was Asian, one was black, and one was mixed race. Median age at diagnosis of CGD was 3 years (IQR 8) and of IBD was 15.5 years (IQR 20). Median age at initiation of ustekinumab was 27.5 years (IQR 14) and median duration on ustekinumab was 10 months (IQR 7). Six had colonic disease, two had ileocolonic disease, and six had perianal disease. Six failed other biologics (n=5 for vedolizumab, n=1 for infliximab, n=1 for adalimumab). Six patients symptomatically improved whereas two had no improvement. Changes in hemoglobin and C-reactive protein were equivocal. Three patients had improved endoscopic findings, two had unimproved findings, and three patients lacked this data. Overall, four patients achieved clinical remission. However, none of the five patients with endoscopic reevaluation achieved endoscopic remission. Three patients discontinued therapy due to lack of response: two required surgery and one underwent stem cell transplant. Fungal pneumonia (n=2), otitis media (n=1), oral herpes simplex virus 1 (n=1), and viral gastroenteritis (n=1) were reported. One infusion reaction occurred. Discussion In our cohort of eight patients with CGD-associated IBD receiving ustekinumab, results were mixed with four patients experiencing some degree of clinical or endoscopic improvement including four who achieved clinical remission. Multiple CGD-related variables may account for the mixed laboratory findings. Four of the five patients with endoscopic reevaluation had pre-existing strictures that would be unlikely to reverse with medical therapy alone. Of these, two had otherwise resolved endoscopic inflammation. Only two patients had no endoscopic improvement. Two serious infections occurred however CGD confers increased infectious susceptibility and no infections lead to discontinuation of therapy. Given these promising results, further formalized study of ustekinumab in CGD-associated IBD is needed." @default.
• W4234095840 created "2022-05-12" @default.
• W4234095840 creator A5007891396 @default.
• W4234095840 creator A5013149726 @default.
• W4234095840 creator A5056552919 @default.
• W4234095840 creator A5060636006 @default.
• W4234095840 creator A5068960425 @default.
• W4234095840 creator A5082458518 @default.
• W4234095840 creator A5083852718 @default.
• W4234095840 date "2021-01-01" @default.
• W4234095840 modified "2023-09-25" @default.
• W4234095840 title "USTEKINUMAB FOR CHRONIC GRANULOMATOUS DISEASE-ASSOCIATED INFLAMMATORY BOWEL DISEASE" @default.
• W4234095840 doi "https://doi.org/10.1093/ibd/izaa347.142" @default.
• W4234095840 hasPublicationYear "2021" @default.
• W4234095840 type Work @default.
• W4234095840 citedByCount "1" @default.
• W4234095840 countsByYear W42340958402021 @default.
• W4234095840 crossrefType "journal-article" @default.
• W4234095840 hasAuthorship W4234095840A5007891396 @default.
• W4234095840 hasAuthorship W4234095840A5013149726 @default.
• W4234095840 hasAuthorship W4234095840A5056552919 @default.
• W4234095840 hasAuthorship W4234095840A5060636006 @default.
• W4234095840 hasAuthorship W4234095840A5068960425 @default.
• W4234095840 hasAuthorship W4234095840A5082458518 @default.
• W4234095840 hasAuthorship W4234095840A5083852718 @default.
• W4234095840 hasConcept C126322002 @default.
• W4234095840 hasConcept C203014093 @default.
• W4234095840 hasConcept C2776207728 @default.
• W4234095840 hasConcept C2777138892 @default.
• W4234095840 hasConcept C2778175462 @default.
• W4234095840 hasConcept C2778260677 @default.
• W4234095840 hasConcept C2778975655 @default.
• W4234095840 hasConcept C2779134260 @default.
• W4234095840 hasConcept C2779280984 @default.
• W4234095840 hasConcept C2780132546 @default.
• W4234095840 hasConcept C2780479503 @default.
• W4234095840 hasConcept C71924100 @default.
• W4234095840 hasConcept C90924648 @default.
• W4234095840 hasConceptScore W4234095840C126322002 @default.
• W4234095840 hasConceptScore W4234095840C203014093 @default.
• W4234095840 hasConceptScore W4234095840C2776207728 @default.
• W4234095840 hasConceptScore W4234095840C2777138892 @default.
• W4234095840 hasConceptScore W4234095840C2778175462 @default.
• W4234095840 hasConceptScore W4234095840C2778260677 @default.
• W4234095840 hasConceptScore W4234095840C2778975655 @default.
• W4234095840 hasConceptScore W4234095840C2779134260 @default.
• W4234095840 hasConceptScore W4234095840C2779280984 @default.
• W4234095840 hasConceptScore W4234095840C2780132546 @default.
• W4234095840 hasConceptScore W4234095840C2780479503 @default.
• W4234095840 hasConceptScore W4234095840C71924100 @default.
• W4234095840 hasConceptScore W4234095840C90924648 @default.
• W4234095840 hasIssue "Supplement_1" @default.
• W4234095840 hasLocation W42340958401 @default.
• W4234095840 hasOpenAccess W4234095840 @default.
• W4234095840 hasPrimaryLocation W42340958401 @default.
• W4234095840 hasRelatedWork W2187503363 @default.
• W4234095840 hasRelatedWork W2326143279 @default.
• W4234095840 hasRelatedWork W2803673833 @default.
• W4234095840 hasRelatedWork W2989681206 @default.
• W4234095840 hasRelatedWork W3125954254 @default.
• W4234095840 hasRelatedWork W3198548344 @default.
• W4234095840 hasRelatedWork W4205286265 @default.
• W4234095840 hasRelatedWork W4213385218 @default.
• W4234095840 hasRelatedWork W4295254747 @default.
• W4234095840 hasRelatedWork W4353047497 @default.
• W4234095840 hasVolume "27" @default.
• W4234095840 isParatext "false" @default.
• W4234095840 isRetracted "false" @default.
• W4234095840 workType "article" @default.